Top Markets
#1 Wibx Wibx +8.04%
#2 Wrapped Flare Wrapped Flare +4.46%
#3 Decred Decred +4.31%
#4 Humanity Humanity +4.26%
#5 Across Protocol Across Protocol +3.82%
#6 Pearl Pearl +3.51%
#7 aelf aelf +3.44%
#8 Audiera Audiera +2.66%
#9 MarsCoin MarsCoin +2.24%
#10 TRIA TRIA +2.06%
Coin of the day
Wibx Wibx
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

SYN
Classificação em ações #30607
Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on... Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on creating treatments for illnesses with significant unmet medical demands. Among its leading product candidates is SYN-004, engineered to neutralize common intravenous beta-lactam antibiotics within the digestive system. This aims to safeguard the gut microbiome, prevent Clostridium difficile infections (CDI), curb the proliferation of harmful bacteria, combat antimicrobial resistance (AMR), and mitigate acute graft-versus-host-disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key asset is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, intended to address both localized gastrointestinal and systemic conditions. The company is also advancing VCN-01, a therapeutic candidate for various cancers, including pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Additional clinical-stage programs include SYN-006, targeting the prevention of aGVHD and infections from carbapenem-resistant enterococci; SYN-007, designed to avert antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for the prevention and treatment of whooping cough (pertussis); and VCN-11, another cancer therapeutic. Synthetic Biologics maintains partnerships with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis supports a Phase 1b/2a clinical trial for SYN-004. The company's main operations are based in Rockville, Maryland.
Preço da ação
$1.02
Última sincronização: 2022-10-13
Valor de mercado
$16.16M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Synthetic Biologics, Inc. (SYN)

Categoria

Healthcare
Margem Operacional de Synthetic Biologics, Inc. (SYN)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Synthetic Biologics, Inc., a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da Synthetic Biologics, Inc. de 2026 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
Não há dados suficientes para as datas fornecidas.
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.